Sentinel lymphonodectomy does not increase the risk of loco-regional cutaneous metastases of malignant melanomas
- PMID: 15737557
- DOI: 10.1016/j.ejca.2004.11.019
Sentinel lymphonodectomy does not increase the risk of loco-regional cutaneous metastases of malignant melanomas
Abstract
With regard to malignant melanoma, the impact of lymph node surgery on the development of loco-regional cutaneous metastases (LCM) has not yet been adequately addressed. However, this aspect is of interest, since sentinel lymphonodectomy (SLNE) has been suspected of causing LCM by inducing entrapment of melanoma cells. We analysed 244 patients with SLNE and compared the data with 199 patients treated with delayed lymph node dissection (DLND) for clinically palpable metastases. Analysis of both groups commenced at the time of excision of the primary tumour, using the Kaplan-Meier method. LCM that appeared as a first recurrence, as well as the overall probability of developing LCM, were recorded. For sentinel-negative patients with a primary melanoma >1mm thick, the 5-year probability of developing LCM as a first recurrence was 6.9 +/- 0.02% (+/-standard error of the mean (SEM)). The probability was 17.6 +/- 0.03% in the DLND group. Comparing the two node-positive subgroups, the probability of developing LCM as a first recurrence was significantly higher in patients with positive SLNE (27.3 +/- 0.05%, P = 0.03). However, the 5-year overall probability of developing LCM did not differ significantly in the node-positive groups (33.3% in the DLND group vs. 33.7% in patients with positive sentinel lymph nodes (SLNs)). Since early excision of lymphatic metastases by SLNE avoids nodal recurrences, thereby prolonging the recurrence-free interval, the chance of LCM to manifest as a first recurrence should inevitably increase. However, the overall in-transit probability is not increased after SLNE.
Similar articles
-
Factors predicting the risk of in-transit recurrence after sentinel lymphonodectomy in patients with cutaneous malignant melanoma.Ann Surg Oncol. 2006 Aug;13(8):1105-12. doi: 10.1245/ASO.2006.07.020. Epub 2006 Jul 24. Ann Surg Oncol. 2006. PMID: 16865591
-
[Prognosis after sentinel node biopsy in malignant melanoma].Ugeskr Laeger. 2006 Jun 19;168(25):2457-62. Ugeskr Laeger. 2006. PMID: 16824370 Danish.
-
Sentinel lymph node status is the most important prognostic factor for thick (> or = 4 mm) melanomas.J Dtsch Dermatol Ges. 2008 Mar;6(3):198-203. doi: 10.1111/j.1610-0387.2007.06569.x. Epub 2007 Dec 17. J Dtsch Dermatol Ges. 2008. PMID: 18093216 English, German.
-
Prognostic heterogeneity after the excision of lymph node metastases in patients with cutaneous melanoma.Surg Oncol. 2011 Mar;20(1):26-34. doi: 10.1016/j.suronc.2009.09.004. Epub 2009 Nov 8. Surg Oncol. 2011. PMID: 19900803 Review.
-
Pathobiology of the sentinel node.Curr Opin Oncol. 2008 Mar;20(2):190-5. doi: 10.1097/CCO.0b013e3282f46d70. Curr Opin Oncol. 2008. PMID: 18300769 Review.
Cited by
-
Value of sentinel node status as a prognostic factor in melanoma: prospective observational study.BMJ. 2006 Jun 17;332(7555):1423. doi: 10.1136/bmj.38849.680509.AE. Epub 2006 May 30. BMJ. 2006. PMID: 16735303 Free PMC article.
-
Surgical management of melanoma: an EORTC Melanoma Group survey.Ecancermedicalscience. 2013 Mar 28;7:294. doi: 10.3332/ecancer.2013.294. Print 2013. Ecancermedicalscience. 2013. PMID: 23589724 Free PMC article.
-
The role of preoperative lymphoscintigraphy in surgery planning for sentinel lymph node biopsy in malignant melanoma.Wien Klin Wochenschr. 2006 May;118(9-10):286-93. doi: 10.1007/s00508-006-0603-4. Wien Klin Wochenschr. 2006. PMID: 16810487
MeSH terms
LinkOut - more resources
Full Text Sources
Medical